Wellbutrin xl 300
Imbalances in these brain chemicals are associated with depressed mood and other symptoms of depression. (NASDAQ:IPXL) and Anchen Pharmaceuticals, Inc. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. Forward-looking statements wellbutrin xl 300 include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U. The product has been launched, pursuant to an Exclusivity Transfer Agreement with Anchen Pharmaceuticals, Inc. Wellbutrin xl 300 about IMPAX Laboratories, Inc. (OTC: IPXL) reports that the U. (NASDAQ: TEVA) announced today that it has commercially shipped Bupropion Hydrochloride Extended-Release Tablets, 300 mg, the generic version of Biovail Corporation’s antidepressant Wellbutrin XL[R] Tablets, pursuant to an agreement with IMPAX Laboratories, Inc. For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products wellbutrin xl 300 through the IMPAX Pharmaceuticals division. "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 To wellbutrin xl 300 the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such risks and uncertainties include, but are not limited to, possible adverse effects resulting from the delisting of IMPAX’s stock, IMPAX’s delay in filing its 2004 Form 10-K, its Form 10-Q for each of the first three quarters of 2005, its Form 10-K for 2005, and its Form 10-Q for each of the first three quarters of 2006, IMPAX’s ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX’s ability to successfully develop and commercialize pharmaceutical products, IMPAX’s reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX’s filings with the Securities and Exchange Commission. If a legal patent infringement suit is commenced within 45 days from receipt of the Notice of Non-Infringement, pursuant to the provisions of the Hatch-Waxman legislation, the FDA cannot approve the generic product for up to a period of 30 months or upon a Court decision of non-infringement — whichever is earlier. IMPAX has submitted wellbutrin xl 300 its filing with the U. Pursuant to Teva’s existing strategic alliance agreement with IMPAX, Teva has U. Biovail Corporation undertakes no obligation to update or revise any forward-looking statement. HAYWARD, Calif. Biovail developed Wellbutrin XL(R) and licensed the product’s worldwide (excluding Canada) sales and distribution rights to GlaxoSmithKline (GSK) in October 2001. And a subsidiary of Teva Pharmaceutical Industries wellbutrin xl 300 ltd. The IMPAX litigation is ongoing, and IMPAX has filed a Wellbutrin xl 300 motion for summary judgment of noninfringement. "In addition, generic Wellbutrin XL is the first of our Tier 3 products to be marketed under the 12-product Strategic Alliance Agreement signed with Teva in July 2001. "We are confident in the strength of our intellectual property rights as they relate to Wellbutrin XL(R), and will Wellbutrin xl 300 defend these vigorously," said Dr.